SUPPLEMENTAL MATERIAL

1. Supplemental Tables I

Rates of good neurological outcome by ASPECTS subgroups

2. Supplemental Tables II

- a. Angiographic collateral grades by sex
- b. Rates of good neurological outcome by collateral grade and sex in patients with TICI 2b/3 reperfusion

3. Supplemental Tables III

Unadjusted outcomes using primary life expectancy calculation

4. Supplemental Tables IV

Unadjusted outcomes using sensitivity analysis life expectancy calculation

5. Supplemental Tables V

Disability-adjusted life year outcomes using sensitivity analysis life expectancy calculation

6. Supplemental Figure I

Forest plot showing change in adjusted disability adjusted life years of SWIFT, STAR, and SWIFT-PRIME study

Supplemental Table I. Rates of good neurological outcome by ASPECTS subgroups

	Male with 90d mRS 0-2 %	Female with 90d mRS 0-2 %	P-value
ASPECTS 0-6	41%	38%	0.83
ASPECTS 7-8	53%	60%	0.46
ASPECTS 9-10	75%	65%	0.24

^{*}Data are reported as %
†Abbreviation: mRS, modified Rankin scale; ASPECTS, Alberta stroke program early CT scan score

Supplemental Table II a. Angiographic collateral grades by sex

	Female No. (%) (n=153)	Male No. (%) (n=120)	p-value
Collateral Grade 0-2	61 (39.9%)	45 (37.5%)	0.71
Collateral Grade 3-4	92 (60.1%)	75 (62.5%)	0.71

^{*}Data are reported as n/N (%)

Supplemental Table II b. Rates of good neurological outcome by collateral grade and sex in patients with TICI 2b/3 reperfusion

	Female with 90d mRS 0-2 n/N (%) (n=149)	Male with 90d mRS 0-2 n/N (%) (n=117)	p-value
Collateral Grade 0-2	40/89 (44.9%)	37/73 (50.7%)	0.53
Collateral Grade 3-4	40/60 (66.7%)	32/44 (72.7%)	0.53

^{*}Data are reported as n/N (%)

†Abbreviation: mRS, modified Rankin scale

Supplemental Table III. Unadjusted outcomes using primary life expectancy calculation

Metric	Male (n=175)	Female (n=214)	p-value*
Age (years)	64 ± 12	69 ± 13	< 0.001
NIHSS at baseline	17 ± 5	17 ± 5	0.31
Full life expectancy	19 ± 9	18 ± 10	0.02
Life expectancy post-stroke	12 ± 9	12 ± 10	0.17
Disability-adjusted life years expected	10 ± 9	9 ± 9	0.48

^{*}p-values from Wilcoxon's nonparametric signed-rank test
†Data are reported as Mean ± SD
‡Abbreviation: NIHSS, national institutes of health stroke scale

Supplemental Table IV. Unadjusted outcomes using sensitivity analysis life expectancy calculation

Metric	Male (n=175)	Female (n=214)	p-value*
Age (years)	64 ± 12	69 ± 13	<0.001
NIHSS at baseline	17 ± 5	17 ± 5	0.31
Full life expectancy	19 ± 9	18 ± 10	0.02
Life expectancy post-stroke	12 ± 9	12 ± 10	0.30
Disability-adjusted life years expected	10 ± 9	10 ± 10	0.63

^{*}p-values from Wilcoxon's nonparametric signed-rank test
†Data are reported as Mean ± SD
‡Abbreviation: NIHSS, national institutes of health stroke scale


Supplemental Table V. Disability-adjusted life year outcomes using sensitivity analysis life expectancy calculation

Parameter	Change in DALY per unit of parameter	Standard Error	p- value
Age (linear, per year of age)	-1.5	0.2	<.0001
Age (quadratic, per year of squared age)	0.007	0.001	<.0001
NIHSS at baseline (linear, per point)	-1.2	0.3	0.0004
Age by NIHSS interaction (quadratic, per year x point)	0.01	0.005	0.0107
Pre-stroke mRS (per point)	-1.4	0.4	0.0007
Atrial fibrillation (yes vs no)	0.5	0.6	0.4289
Smoking status (yes vs no)	0.7	0.8	0.3633
IV-tPA administered (yes vs no)	0.05	0.6	0.9339
Female gender (versus male)	11.2	3.1	0.0003
Per year of age, female gender (versus male)	-0.13	0.05	0.0047

^{*}Abbreviation: NIHSS, national institutes of health stroke scale; mRS, modified Rankin Scale; IV-

tPA, intravenous tissue plasminogen activator

Supplemental Figure I. Forest plot showing disability adjusted life years expectancy (DALYs) of SWIFT, STAR, and SWIFT-PRIME study



Multivariate model for each study showing change in DALYs with adjusting parameters. *Abbreviation: NIHSS, national institutes of health stroke scale; tPA, tissue plasminogen activator; mRS, modified Rankin scale; DALYs, disability-adjusted life years